AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1669137 — intervention group
Group type: COMPARATOR
Intervention: Intermittent administration of streptokinase (500,000 IU initial dose, 250,000 IU every 12 h)
Number of subjects: 55
Study 1669137 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of streptokinase
Number of subjects: 55
Study 1669137 — intervention group
Group type: COMPARATOR
Intervention: Intermittent administration of streptokinase
Number of subjects: 55
Study 6120902 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 g atenolol
Number of subjects: 9
Study 6120902 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.08 g propranolol
Number of subjects: 9
Study 6120902 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 30832625 — intervention group
Group type: EXPERIMENTAL
Intervention: Occasional snorers
Number of subjects: 3794
Study 30832625 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual snorers
Number of subjects: 3794
Study 30832625 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI ≥ 24
Number of subjects: 3794
Study 30832625 — intervention group
Group type: EXPERIMENTAL
Intervention: Additive interaction between snoring and BMI
Number of subjects: 3794
Study 27888045 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (18 μg single dose)
Number of subjects: 18
Study 27888045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 24805971 — intervention group
Group type: EXPERIMENTAL
Intervention: Being a spouse
Number of subjects: 103
Study 24805971 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 103
Study 24805971 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing scores on the Research Attitudes Questionnaire
Number of subjects: 103
Study 24805971 — intervention group
Group type: EXPERIMENTAL
Intervention: Research attitudes
Number of subjects: 103
Study 24805971 — intervention group
Group type: EXPERIMENTAL
Intervention: Being a spouse vs adult child
Number of subjects: 103
Study 23292159 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nebulized inhalative epinephrine
Number of subjects: 8
Study 23292159 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg nebulized inhalative epinephrine
Number of subjects: 8
Study 23292159 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg intramuscular epinephrine
Number of subjects: 8
Study 23292159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 23292159 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalative administrations of epinephrine
Number of subjects: 8
Study 23292159 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg inhalative epinephrine
Number of subjects: 8
Study 20381082 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 50
Study 20381082 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 50
Study 19040458 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care + blowing soap bubbles
Number of subjects: 28
Study 19040458 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care + heated pillow
Number of subjects: 28
Study 19040458 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 28
Study 19040458 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care + intervention (blowing soap bubbles or heated pillow)
Number of subjects: 28
Study 16426956 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery in both eyes (intervention group)
Number of subjects: 296
Study 16426956 — intervention group
Group type: COMPARATOR
Intervention: Surgery in one eye only (control group)
Number of subjects: 296
Study 15155959 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose argatroban (100 microg/kg bolus, 3 microg/kg per minute)
Number of subjects: 171
Study 15155959 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose argatroban (100 microg/kg bolus, 1 microg/kg per minute)
Number of subjects: 171
Study 15155959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 15155959 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including asymptomatic ICH)
Number of subjects: 171
Study 11730824 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg per day
Number of subjects: 18
Study 11730824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9164990 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in fat (50%) and poor in dietary fiber
Number of subjects: 7
Study 9164990 — intervention group
Group type: COMPARATOR
Intervention: Vegetarian diet poor in fat (20%) and rich in dietary fiber
Number of subjects: 7
Study 9164990 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in fat and poor in dietary fiber
Number of subjects: 7
Study 9164990 — intervention group
Group type: COMPARATOR
Intervention: Vegetarian diet poor in fat and rich in dietary fiber
Number of subjects: 7
Study 8122501 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cost multicomponent intervention program including information about the dangers of smoking in pregnancy and a self-help manual for a 10 day program
Number of subjects: 104
Study 8122501 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving a control ultrasound around the 32nd week of pregnancy with two encouraging reminders mailed before and after
Number of subjects: 104
Study 8122501 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cost multicomponent intervention program
Number of subjects: 104
Study 8122501 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study 2504855 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 18
Study 2504855 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil
Number of subjects: 18
Study 1059540 — intervention group
Group type: EXPERIMENTAL
Intervention: 9% stannous-fluoride treatment on right incisors before extraction
Number of subjects: 10
Study 1059540 — intervention group
Group type: COMPARATOR
Intervention: Unfluoridated left incisive teeth
Number of subjects: 10
Study 31130270 — intervention group
Group type: EXPERIMENTAL
Intervention: Buteyko breathing technique in conjunction with medical management (nasal steroid)
Number of subjects: 51
Study 26135277 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention in an emergency-setting
Number of subjects: 0
Study 26135277 — intervention group
Group type: COMPARATOR
Intervention: Established indicated prevention program
Number of subjects: 0
Study 23203942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural model of eating disorders
Number of subjects: 1451
Study 21245669 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Practice (MP) - 30 minutes of MP before each laparoscopic cholecystectomy (LC)
Number of subjects: 20
Study 21245669 — intervention group
Group type: COMPARATOR
Intervention: Control - viewed an online lecture
Number of subjects: 20
Study 21245669 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Practice (MP)
Number of subjects: 20
Study 18310175 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-practice behavioral program
Number of subjects: 134
Study 18310175 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 134
Study 16526307 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 14586323 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency cerclage and indomethacin
Number of subjects: 23
Study 14586323 — intervention group
Group type: COMPARATOR
Intervention: Bed rest only
Number of subjects: 23
Study 11029565 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine inhalation (1%, 4%, and 10% concentrations, total doses of 0.5, 2.0, and 5.0 mg kg‐1)
Number of subjects: 15
Study 11029565 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine inhalation (1%, 4%, and 10% concentrations)
Number of subjects: 15
Study 11029565 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine inhalation (4% and 10% concentrations)
Number of subjects: 15
Study 11029565 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine inhalation
Number of subjects: 15
Study 11029565 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine inhalation (4% solution)
Number of subjects: 15
Study 8803857 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-efficacy condition
Number of subjects: 40
Study 8803857 — intervention group
Group type: COMPARATOR
Intervention: Low self-efficacy condition
Number of subjects: 40
Study 1999002 — intervention group
Group type: EXPERIMENTAL
Intervention: 250-mg flutamide tablets three times daily
Number of subjects: 8
Study 1999002 — intervention group
Group type: COMPARATOR
Intervention: 400-mg sustained-release flutamide tablets twice daily
Number of subjects: 8
Study 6422790 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.3 mg i.v.)
Number of subjects: 60
Study 6422790 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (30 mg i.v.)
Number of subjects: 60
Study 31109812 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists' knowledge of naloxone formulations
Number of subjects: 79
Study 31109812 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists' ability to counsel on opioid overdose response
Number of subjects: 79
Study 31109812 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists' knowledge of rescue breathing and recovery position
Number of subjects: 79
Study 30239376 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple arterial grafts
Number of subjects: 0
Study 30239376 — intervention group
Group type: COMPARATOR
Intervention: Single arterial grafts
Number of subjects: 0
Study 30239376 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery as a second graft
Number of subjects: 0
Study 30239376 — intervention group
Group type: COMPARATOR
Intervention: Saphenous vein as a second graft
Number of subjects: 0
Study 27181775 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg atorvastatin
Number of subjects: 0
Study 27181775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24123153 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-breathing cardiac MR perfusion sequence with slice tracking
Number of subjects: 20
Study 24123153 — intervention group
Group type: COMPARATOR
Intervention: Conventional perfusion sequence (without slice tracking)
Number of subjects: 20
Study 22648720 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available pureed meats
Number of subjects: 45
Study 22648720 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-and-zinc-fortified infant cereal (IZFC)
Number of subjects: 45
Study 22648720 — intervention group
Group type: COMPARATOR
Intervention: Whole-grain, iron-only-fortified infant cereal (IFC)
Number of subjects: 45
Study 19113918 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (TPTD)
Number of subjects: 100
Study 19113918 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 100
Study 17895235 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% w/v lidocaine with hyaluronidase 15 IU ml(‐1)
Number of subjects: 62
Study 17895235 — intervention group
Group type: COMPARATOR
Intervention: 2% w/v lidocaine
Number of subjects: 62
Study 15167308 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein with 96 mg isoflavones/day
Number of subjects: 65
Study 15167308 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy with 52 mg isoflavones/day
Number of subjects: 65
Study 15167308 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy without isoflavones (< 4 mg isoflavones/day)
Number of subjects: 65
Study 15167308 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 65
Study 12501904 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medication
Number of subjects: 0
Study 12501904 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive agents in white-coat hypertension
Number of subjects: 0
Study 9679792 — intervention group
Group type: EXPERIMENTAL
Intervention: Minidose warfarin (1.25 mg/d)
Number of subjects: 677
Study 9679792 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin plus aspirin (1.25 mg/d + 300 mg/d)
Number of subjects: 677
Study 9679792 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg/d)
Number of subjects: 677
Study 9679792 — intervention group
Group type: COMPARATOR
Intervention: Adjusted-dose warfarin (INR 2.0-3.0)
Number of subjects: 677
Study 9679792 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 677
Study 10068745 — intervention group
Group type: EXPERIMENTAL
Intervention: bismuth‐metronidazole‐tetracycline‐ranitidine
Number of subjects: 118
Study 10068745 — intervention group
Group type: EXPERIMENTAL
Intervention: bismuth‐metronidazole‐amoxicillin‐ranitidine
Number of subjects: 118
Study 10068745 — intervention group
Group type: COMPARATOR
Intervention: NSAID's use
Number of subjects: 118
Study 10068745 — intervention group
Group type: COMPARATOR
Intervention: Persistent peptic ulcer
Number of subjects: 118
Study 2652906 — intervention group
Group type: COMPARATOR
Intervention: Nisoldipine (calcium-channel blocker)
Number of subjects: 18
Study 2652906 — intervention group
Group type: COMPARATOR
Intervention: Heather-index (impedance cardiography)
Number of subjects: 18
Study 319713 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral atropine sulfate 0.5 mg four times a day
Number of subjects: 6
Study 319713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29415592 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted technique of suturing
Number of subjects: 0
Study 29415592 — intervention group
Group type: COMPARATOR
Intervention: Continuous technique of suturing
Number of subjects: 0
Study 29041942 — intervention group
Group type: EXPERIMENTAL
Intervention: ALO-02
Number of subjects: 410
Study 25416496 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepeta menthoides capsules (400 mg) and conventional drugs
Number of subjects: 43
Study 25416496 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuscuta planiflora capsules (500 mg) and conventional drugs
Number of subjects: 43
Study 25416496 — intervention group
Group type: COMPARATOR
Intervention: Conventional drugs only
Number of subjects: 43
Study 23775051 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 106
Study 23775051 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 106
Study 21782375 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring tendon autograft
Number of subjects: 78
Study 21782375 — intervention group
Group type: COMPARATOR
Intervention: Irradiated allograft
Number of subjects: 78
Study 20516268 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU vitamin D(3) daily for 6 months
Number of subjects: 92
Study 20516268 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg elemental calcium daily for 6 months
Number of subjects: 92
Study 20516268 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vitamin D(3) and calcium
Number of subjects: 92
Study 20516268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 16393311 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide foam (2 mg/25 mL)
Number of subjects: 541
Study 16393311 — intervention group
Group type: COMPARATOR
Intervention: Budesonide enema (2 mg/100 mL)
Number of subjects: 541
Study 16393311 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide foam
Number of subjects: 541
Study 16393311 — intervention group
Group type: COMPARATOR
Intervention: Budesonide enema
Number of subjects: 541
Study 15279915 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive video intervention
Number of subjects: 300
Study 15279915 — intervention group
Group type: COMPARATOR
Intervention: High-quality informational intervention (book form)
Number of subjects: 300
Study 15279915 — intervention group
Group type: COMPARATOR
Intervention: Commercially available brochures
Number of subjects: 300
Study 11524314 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia and analgesia (TEA) for 96 hours
Number of subjects: 420
Study 11524314 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA) with narcotic analgesia for 72 hours
Number of subjects: 420
Study 9348757 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 0
Study 9348757 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 0
Study 9348757 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training
Number of subjects: 0
Study 9348757 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity program including strength training
Number of subjects: 0
Study 9348757 — intervention group
Group type: COMPARATOR
Intervention: Psychoactive drugs (e.g., benzodiazepines)
Number of subjects: 0
Study 9348757 — intervention group
Group type: COMPARATOR
Intervention: Trophic factors
Number of subjects: 0
Study 8281985 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg acetylsalicylic acid (ASA) infused intravenously
Number of subjects: 36
Study 8281985 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 36
Study 8281985 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA infusion
Number of subjects: 36
Study 2947334 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 100
Study 2947334 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 100
Study 2947334 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 100
Study 29540280 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver perspectives on asthma management
Number of subjects: 15
Study 27135598 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor milk
Number of subjects: 373
Study 27135598 — intervention group
Group type: COMPARATOR
Intervention: Formula
Number of subjects: 373
Study 24665827 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 157
Study 24665827 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 157
Study 24665827 — intervention group
Group type: COMPARATOR
Intervention: PF4/H antibody-positive patients
Number of subjects: 157
Study 24665827 — intervention group
Group type: COMPARATOR
Intervention: PF4/H antibody-positive patients who survived thrombosis
Number of subjects: 157
Study 22311204 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS treatment
Number of subjects: 0
Study 22311204 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (WTL) group
Number of subjects: 0
Study 21088095 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (starting dose 5 mg/day, uptitrated to 10, 20, or 40 mg/day as needed)
Number of subjects: 277
Study 21088095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study 21088095 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 277
Study 18356758 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based cognitive-behavioral therapy (CBT)
Number of subjects: 42
Study 18356758 — intervention group
Group type: COMPARATOR
Intervention: Family-based relaxation treatment (RT)
Number of subjects: 42
Study 16008322 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostina (2 capsules twice daily for 12 weeks)
Number of subjects: 40
Study 16008322 — intervention group
Group type: COMPARATOR
Intervention: Terazosin (2 mg at bedtime for 12 weeks)
Number of subjects: 40
Study 12466730 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine bolus injection (n = 44)
Number of subjects: 77
Study 12466730 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine continuous drip in normal saline (n = 33)
Number of subjects: 77
Study 10367320 — intervention group
Group type: EXPERIMENTAL
Intervention: Avonex 6.0 MUI (30 micrograms) administered by intramuscular injection weekly
Number of subjects: 301
Study 10367320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 10367320 — intervention group
Group type: EXPERIMENTAL
Intervention: Avonex
Number of subjects: 301
Study 7747534 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole-hydrocortisone cream and ketoconazole shampoo (Group A)
Number of subjects: 60
Study 7747534 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone cream and placebo shampoo (Group B)
Number of subjects: 60
Study 2157982 — intervention group
Group type: EXPERIMENTAL
Intervention: 33B3.1 (10 mg per day)
Number of subjects: 100
Study 2157982 — intervention group
Group type: EXPERIMENTAL
Intervention: 33B3.1
Number of subjects: 100
Study 2157982 — intervention group
Group type: COMPARATOR
Intervention: 33B3.1 and antithymocyte globulin
Number of subjects: 100
Study 2157982 — intervention group
Group type: COMPARATOR
Intervention: Antithymocyte globulin
Number of subjects: 100
Study 393377 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment plus adjuvant therapy with DTIC and Corynebacterium parvum
Number of subjects: 61
Study 393377 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment only (control group)
Number of subjects: 61
Study 30660472 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based radiomics classifier using four post-T1WI-MRI radiomics features
Number of subjects: 127
Study 30660472 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics classifier combined with clinical data
Number of subjects: 127
Study 30660472 — intervention group
Group type: COMPARATOR
Intervention: Clinical risk model (Karnofsky performance status, radiation therapy)
Number of subjects: 127
Study 26934834 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-end-rounded brushes
Number of subjects: 46
Study 26934834 — intervention group
Group type: COMPARATOR
Intervention: 40-50% end-rounded brushes
Number of subjects: 46
Study 26934834 — intervention group
Group type: COMPARATOR
Intervention: >90% end-rounded brushes
Number of subjects: 46
Study 25992877 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight intraoperative glucose control with hyperinsulinemic-normoglycemic clamp (target blood glucose, 80 to 110 mg/dl)
Number of subjects: 198
Study 25992877 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (conventional insulin administration with blood glucose target, <150 mg/dl)
Number of subjects: 198
Study 23351820 — intervention group
Group type: EXPERIMENTAL
Intervention: PA32540 + clopidogrel (300 mg loading/75 mg maintenance) 10 hours later
Number of subjects: 30